Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 As Norovirus Lead
Portfolio Pulse from Happy Mohamed
Cocrystal Pharma, Inc. (NASDAQ:COCP) has selected its novel oral protease inhibitor CDI-988 as a potential oral therapy for norovirus. The Phase 1 study of CDI-988 is approved by Australia Human Research Ethics Committees. Norovirus represents a significant unmet medical need with no approved treatments or vaccines. CDI-988 was specifically designed as a broad-spectrum antiviral inhibitor and has shown potent antiviral activity against a panel of pandemic GII.4 norovirus proteases.
August 08, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cocrystal Pharma's selection of CDI-988 as a potential oral therapy for norovirus could potentially open a significant market for the company, given the lack of approved treatments or vaccines for the virus.
The news is directly related to Cocrystal Pharma and its product development. The lack of approved treatments or vaccines for norovirus represents a significant unmet medical need, which could potentially open a large market for the company if CDI-988 proves to be effective and safe in further clinical trials.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100